Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028. Fair value range: low $94.9, high $147, with mid-point at $121.
Stock analysis
Merck & Co. Inc.MRK Merck & Co. Inc. fair value $121–$147
Heavy concentration risk in Keytruda, which faces loss of exclusivity in 2028.
Dependency on future M&A and ADC pipeline execution to replace lost revenue.
Primary valuation anchor focuses on near-term forward earnings over stale trailing cash flows.
Fair value
$121
Margin of safety
+6.9%
Confidence
84/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$112.30Price
FV $120.61
High $146.75
Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028.
Intangible Assets (Patents)
Intangible Assets (Patents)
Economies of Scale
Economies of Scale
Cycle upside
Accelerating M&A and robust pipeline readouts across the biopharma sector.
§2 看空情景
A severe stress test assumes structural earnings decline post-2028 as Keytruda revenues drop, combined with a failure to realize ADC revenue and M&A integration issues, compressing gross margins.
该论点可能失败的方式
Severe Keytruda Cliff
· High
Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.
FV impact
Down to $94.87
Trigger
2028-2030
ADC Pipeline Failure
· Medium
Late-stage clinical failures in the Antibody-Drug Conjugate pipeline erode future growth vectors, stalling the dividend trajectory.
FV impact
Loss of terminal growth and multiple derating
Trigger
2026-2028
Draconian IRA Pricing
· Medium
Aggressive regulatory pricing pressures from the IRA compress margins more sharply than modeled, stunting near-term operating cash flows.
FV impact
Terminal margin deterioration
Trigger
2026-2029
需关注的早期预警信号
指标
当前
触发阈值
Slowdown in Keytruda quarterly sales growth pre-2028
Monitor
Deterioration versus the report thesis
Negative FDA decisions on late-stage ADC candidates
Monitor
Deterioration versus the report thesis
Escalating R&D costs without proportional revenue gains
Monitor
Deterioration versus the report thesis
Unfavorable shifts in gross margin trajectories
Monitor
Deterioration versus the report thesis
Management signaling a pause or slowing of dividend growth
Monitor
Deterioration versus the report thesis
§3 财务历史
损益表 — 最近六期
项目
T−0
T−1
T−2
T−3
CAGR
期间
2022-12-31
2023-12-31
2024-12-31
2025-12-31
Trend
营业收入
$59.28B
$60.12B
$64.17B
$65.01B
+3.1%
毛利
$41.87B
$43.99B
$48.98B
$48.63B
+5.1%
营业利润
$18.28B
$2.95B
$20.22B
$22.11B
+6.5%
净利润
$14.52B
$365.0M
$17.12B
$18.25B
+7.9%
每股收益（摊薄）
$5.71
$0.14
$6.74
$7.28
+8.4%
EBITDA
$21.32B
$6.91B
$25.71B
$28.26B
+9.9%
研发
$13.55B
$30.53B
$17.94B
$15.79B
+5.2%
销售管理费用
$10.04B
$10.50B
$10.82B
$10.73B
+2.2%
质量评分
Piotroski F 评分
4 / 9
0–9 质量综合
Altman Z 评分
3.87
破产风险 (>3 安全)
Beneish M 评分
-2.27
盈利操纵风险
OCF / 净利润
0.9×
>1 表示盈利质量高
会计质量门槛
Pass
经行业调整门槛
ROIC
17.4%
投入资本回报率
第 3 节
Numbers analysis
现金流
Cash-flow quality is reflected in the OCF / net income, accounting-quality, and ROIC rows above.
资本配置
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
个人订阅用户 — §4 及之后还有 11 个章节
阅读完整分析 — 还有 11 个章节。
Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.
Based on our latest independent analysis, MRK looks modestly undervalued. The current price is $112 versus a composite fair-value midpoint of $121 (range $94.9–$147), which implies roughly 7.4% upside to the midpoint.
Our composite fair-value range for MRK is $94.9–$147, with a midpoint of $121. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for Merck & Co. Inc.'s archetype.
Our current rating for MRK is Hold with a confidence score of 84/100. Hold. Current price of $112.30 represents limited upside of 7.4% to our $120.61 fair value mid-point, appropriately pricing in the pipeline transition risks. This is independent research for educational purposes, not personalized investment advice.
The top risks our latest report flags for Merck & Co. Inc. are: Severe Keytruda Cliff; ADC Pipeline Failure; Draconian IRA Pricing. The single biggest risk is Severe Keytruda Cliff: Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.
Our current rating for MRK is Hold, issued with a confidence score of 84/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($94.9–$147) versus the current price of $112.
Merck & Co. Inc. is classified as a mature-dividend stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for MRK.
